UK cost watch­dog drafts guid­ance against 5 Covid treat­ments and J&J de­pres­sion med

It looks like five Covid treat­ments like­ly won’t make the NICE list this year, the UK’s cost-ef­fec­tive­ness watch­dog re­cent­ly an­nounced, and nei­ther will J&J’s es­ke­t­a­mine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA